
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol. , 08 November 2022
Sec. Ethnopharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1054143
This article is a correction to:
An Integrative Serum Pharmacology-Based Approach to Study the Anti-Tumor Activity of B. paniculatum Aqueous Bulb Extract on the Human Hepatocellular Carcinoma Cell Line BEL-7404
by Feng X, Ma G, Shi H, Wang Y and Chao X (2020). Front. Pharmacol. 11:01261. doi: 10.3389/fphar.2020.01261
In the published article, there was an error in the Funding statement. We missed to include the funding support from the Education Department of Shaanxi Provincial Government of China (20JK0588). The correct Funding statement appears below.
“This study was supported by the fund from the Subject Innovation Team of Shaanxi University of Chinese Medicine (2019YS05), the Basic Scientific Research Project of Shaanxi Province (2020JQ-867) and the Education Department of Shaanxi Provincial Government of China (20JK0588)”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: traditional Chinese medicine, bolbostemma paniculatum, tu bei mu, hepatocellular carcinoma, network pharmacology
Citation: Feng X, Ma G, Shi H, Wang Y and Chao X (2022) Corrigendum: An integrative serum pharmacology-based approach to study the anti-tumor activity of B. Paniculatum aqueous bulb extract on the human hepatocellular carcinoma cell line BEL-7404. Front. Pharmacol. 13:1054143. doi: 10.3389/fphar.2022.1054143
Received: 26 September 2022; Accepted: 25 October 2022;
Published: 08 November 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Feng, Ma, Shi, Wang and Chao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xu Chao, Q2hhb3h1MjAwNEAxMjYuY29t
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.